ALEXANDRIA, Va., June 9 -- United States Patent no. 12,286,430, issued on April 29, was assigned to BeiGene Ltd. (Grand Cayman, Cayman Islands).
"Bcl-2 inhibitor" was invented by Hai Xue (Beijing), Yunhang Guo (Beijing) and Zhiwei Wang (Beijing).
According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein is a compound of Formula (I) for inhibiting both Bcl-2 wild type and mutated Bcl-2, in particular, Bcl-2 G101V and D103Y, and a method of using the compound disclosed herein for treating dysregulated apoptotic diseases."
The patent was filed on April 14, 2021, under Application No. 17/916,845.
*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph...